FDA-&-EMA-New-Drug Approvals(Mid-2020 Recap)-insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BBV87

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: CEPI

            Deal Size: $14.1 million Upfront Cash: Undisclosed

            Deal Type: Funding May 03, 2020

            Details:

            CEPI will fund the consortium for vaccine manufacturing and clinical development of a 2-dose live-inactivated vaccine (BBV87) against Chikungunya. The partnering agreement will finance a multi-centre Phase 2/3 adaptive clinical trial to be conducted by IVI.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GYROX-1

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: University of Tokyo Edge Capital

            Deal Size: $7.5 million Upfront Cash: Undisclosed

            Deal Type: Financing April 22, 2020

            Details:

            This investment enables Bugworks to complete Phase 1 studies for its GYROX series Intravenous drug candidate and advance an Oral lead towards clinical development.